Think of the spleen as the body's central immune command post. It is the largest immune organ and the only one that filters the entire bloodstream directly — roughly 5% of every heartbeat passes through it. This gives the spleen a unique job: it constantly screens circulating blood for foreign particles, aged cells, and antigens, then decides how the immune system should respond. The organ is organized into three functional zones that work together. The red pulp acts as a filtration bed where blood is cleaned by resident F4/80+ CD68+ macrophages. The marginal zone sits at the boundary between blood and immune tissue, functioning as an early-warning sentinel populated by MARCO+ SIGN-R1+ macrophages and CD21hi CD23lo marginal zone B cells that capture blood-borne threats. The white pulp is the adaptive immunity control center, packed with T cells, B cells, and CD11c+ dendritic cells (DCs) arranged so that antigen presentation and lymphocyte activation happen in the same confined space. For any therapy that aims to retrain or activate the immune system — whether to fight cancer, build vaccine immunity, or calm autoimmunity — reaching these splenic immune cells is not optional. It is the difference between delivering a payload the immune system can actually use and one that is simply discarded.
Standard LNPs send most of their cargo to the liver, where it is wasted from an immunological standpoint. Redirecting that cargo to the spleen instead unlocks four concrete therapeutic opportunities. First, in cancer immunotherapy, spleen-targeted mRNA LNPs can train CD8+ T cells right inside the splenic white pulp, generating anti-tumor fighters that then travel to the tumor — preclinical data show stronger immunity than liver-dominated formulations at the same dose. Second, in vaccination, delivering antigen-encoding mRNA to splenic B cells and marginal zone cells drives high-affinity antibody production, with spleen-targeted versions producing 5- to 10-fold higher neutralizing titers. Third, in autoimmune disease, spleen-selective delivery of self-antigens together with tolerogenic signals (such as rapamycin or IL-10) can expand regulatory T cells and switch off autoreactive responses — a disease-modifying approach rather than symptom suppression. Fourth, in infectious disease, rapid engagement of marginal zone B cells produces fast IgM and IgG defenses against blood-stage pathogens. In every case, the requirement is the same: enough LNP must reach the right splenic compartment to engage the right immune cell. This is precisely why spleen-targeted LNP development has become a priority for research teams across these indications.
Functional delivery to splenic immune cells is not a single event but a four-stage cascade in which each step presents a distinct formulation challenge. A particle that passes through all four stages successfully — reaching the spleen, engaging the right cell, gaining intracellular access, and releasing its payload into the correct subcellular compartment — produces the intended immunological outcome, while failure at any stage results in wasted dose or off-target effects. Understanding this cascade is essential for rational design of spleen-selective LNPs.
Following intravenous administration, LNPs enter the systemic circulation and are immediately subject to splenic filtration. The splenic red pulp contains venous sinuses lined by interendothelial slits approximately 200-500 nm in width, through which blood cells and circulating particles must pass to re-enter the venous circulation. Particles smaller than these slits transit rapidly; particles in the 40-150 nm range are retained within the splenic parenchyma at rates determined by their size, charge, and deformability. This filtration step is the first major divergence point from hepatic routing: particles that are too large (>250 nm) are cleared primarily by hepatic Kupffer cells before reaching the spleen, while appropriately sized particles gain splenic access. The open vs. closed circulation architecture of the spleen further influences residence time and the probability of immune cell encounter.
Within seconds of blood contact, LNPs adsorb a dynamic layer of plasma proteins — the protein corona — that determines their biological identity. Standard hepatic LNPs adsorb apolipoprotein E (ApoE), creating a corona recognized by low-density lipoprotein receptor (LDLR) on hepatocytes. Spleen-targeted LNPs, by contrast, are engineered to recruit a different corona: anionic helper lipids and charge-modulating phospholipids can promote adsorption of IgM, complement C3, and distinct opsonins that engage complement receptor 3 (CR3) and Fc receptors on splenic macrophages and DCs. The corona composition is exquisitely sensitive to surface chemistry — PEG anchor length, ionizable lipid pKa, helper lipid identity, and lipid molar ratio all shift the adsorbed protein profile — making corona engineering a central lever for spleen selectivity. Properly formulated spleen-targeted LNPs maintain colloidal stability throughout this stage rather than aggregating, which would trigger nonspecific clearance.
Once within the splenic microenvironment, LNPs are internalized by immune cells through multiple pathways: macrophage and marginal zone scavenger receptor-mediated phagocytosis, C-type lectin receptor endocytosis on DCs, B cell receptor-mediated uptake in follicles, and integrin or chemokine receptor engagement on T cells. The dominant uptake route depends on the target cell and the surface functionalization. Passive spleen-targeted LNPs are taken up primarily by red pulp and marginal zone macrophages, while actively targeted LNPs engage their cognate receptors on specific subsets (e.g., anti-CD11c for DCs, anti-CD19 for B cells). The efficiency of this stage determines how much payload reaches the intracellular space, but uptake alone is insufficient — the cargo must still escape the endolysosomal compartment to act.
The final and most failure-prone stage is endosomal escape. Internalized LNPs are delivered to endolysosomes with acidic pH (5.0-6.0) and degradative enzymes. Protonation of the ionizable lipid at this pH triggers a conformational change that disrupts the endosomal membrane, releasing the payload into the cytosol. For mRNA and saRNA, cytosolic delivery enables translation; for siRNA and ASO, the cargo must reach the RNA-induced silencing complex (RISC); for protein antigens, cytosolic or MHC-loading compartment delivery determines presentation route. Phagocytic splenic cells are particularly challenging at this stage due to their high endolysosomal degradative capacity — the same machinery that captures LNPs rapidly destroys their cargo. Enhancing endosomal escape through fusogenic helper lipids (DOPE), pH-responsive components, or optimized ionizable lipid chemistry is therefore critical. LNP endosomal escape evaluation provides the assays needed to confirm that uptake translates into productive payload action rather than lysosomal degradation.
Table.1 Four-Stage Spleen-Targeted LNP Delivery -- Challenge and Requirement-Strategy.
| Stage | Delivery Challenge Encountered | LNP Requirement and Formulation Strategy |
| Stage I Transport & Filtration | Particles larger than 250 nm are trapped by liver Kupffer cells before they ever reach the spleen, wasting the dose. | Requirement: LNP must stay small enough (40-150 nm) to pass the spleen's 200-500 nm filtration slits while avoiding early liver capture. Strategy: Control particle diameter via microfluidic production with narrow size distribution. |
| Stage II Corona & Recognition | Standard LNPs grab apolipoprotein E (ApoE), which flags them for uptake by liver cells via the LDLR pathway, missing the spleen entirely. | Requirement: LNP must build a spleen-friendly protein coat (IgM, complement) on its surface instead of a liver-friendly ApoE corona. Strategy: Incorporate anionic or charge-modulating phospholipids; tune surface charge and PEG-lipid architecture to reshape the corona. |
| Stage III Cellular Uptake | Passive LNPs are eaten mainly by macrophages; uptake by the wrong immune subset wastes the payload and fails to engage target cells. | Requirement: LNP must engage the intended splenic immune cell (macrophage, DC, B, or T cell) so it is internalized by the right population. Strategy: Display targeting ligands (mannose, antibody, peptide, aptamer) on the surface to steer uptake. |
| Stage IV Escape & Action | Phagocytic splenic cells degrade the cargo inside endolysosomes before it escapes, killing the payload before it can function. | Requirement: LNP must break out of the endolysosome and release the payload into the cytosol where it can act. Strategy: Use fusogenic DOPE helper lipid, pH-responsive peptides, and optimized ionizable lipid pKa to drive escape. |
Passive targeting strategies exploit the intrinsic relationship between LNP physicochemical properties and biological fate — particle size, surface charge, PEGylation architecture, ionizable lipid pKa, and helper lipid composition — to shift the biodistribution equilibrium from hepatic dominance toward splenic accumulation. Unlike active targeting, which requires ligand synthesis and conjugation, passive strategies rely on tunable formulation parameters that can be systematically screened using microfluidic manufacturing platforms. The following sections detail how each parameter can be engineered to favor spleen-selective delivery, with practical formulation windows derived from recent systematic studies.
Particle size is arguably the single most influential parameter governing splenic access. Below 100 nm, LNPs penetrate the red pulp efficiently and distribute throughout the organ, with the 40-80 nm range providing an optimal balance of splenic entry and retention. Particles in the 100-200 nm range preferentially accumulate in the marginal zone, where slower blood flow and macrophage scavenger receptor expression favor particle capture. Above 200 nm, passive splenic entry is physically restricted, and particles are cleared primarily by hepatic Kupffer cells. Systematic studies using ionizable lipid nanoparticles with controlled size distributions have confirmed that reducing mean particle diameter from approximately 100 nm to 50 nm can increase the spleen-to-liver accumulation ratio by 2- to 3-fold, primarily by decreasing hepatocyte recognition while maintaining splenic filtration efficiency. Microfluidic LNP production platforms now enable routine manufacturing of LNPs with mean diameters in the 30-80 nm range and polydispersity indices below 0.1, providing the narrow size distributions that reproducible spleen targeting demands.
Table.2 Particle Size and Splenic Distribution Outcomes.
| Size Range | Dominant Splenic Compartment | Liver/Spleen Ratio | Key Immune Cells Engaged | Formulation Guidance |
| <30 nm | Red pulp — rapid transit, minimal retention | >10:1 | Limited; renal clearance possible | Avoid for spleen targeting |
| 40-80 nm | Red pulp and marginal zone | 3:1 to 8:1 | Red pulp macrophages, marginal zone macrophages, DCs | Target range for spleen-selective delivery |
| 80-150 nm | Marginal zone | 5:1 to 15:1 | Marginal zone macrophages, B cells | Suitable for marginal zone targeting |
| 150-250 nm | Marginal zone and red pulp | 10:1 to 30:1 | Red pulp macrophages; limited DC engagement | Combine with active targeting |
| >250 nm | Red pulp — mechanical filtration | >20:1 | Red pulp macrophages only | Not recommended |
The zeta potential of LNPs dictates their interactions with serum proteins, cell membranes, and the extracellular matrix of target organs. Strongly cationic LNPs (>+15 mV) are rapidly opsonized and cleared by the mononuclear phagocyte system, with a significant fraction trapped in the pulmonary capillary bed. Moderately cationic particles (+5 to +15 mV) adsorb ApoE efficiently and follow the canonical hepatic LDLR pathway. Neutral to slightly negative LNPs (-10 to +5 mV) show the most favorable spleen-to-liver ratios, as reduced positive charge density diminishes ApoE adsorption and hepatocyte recognition while permitting interaction with scavenger receptors on splenic macrophages. LNP zeta potential optimization through iterative adjustment of ionizable-to-helper lipid ratios and PEG-lipid content provides a direct lever for tuning splenic accumulation without requiring ligand conjugation.
Table.3 Zeta Potential and Organ Biodistribution Patterns.
| Zeta Potential | Primary Site | Spleen/Liver Ratio | Corona Mechanism | Strategy |
| +15 to +30 mV | Lung and liver | <0.05 | Opsonin adsorption; complement | Reduce cationic lipid; add PEG |
| +5 to +15 mV | Liver (ApoE/LDLR) | 0.05-0.15 | ApoE-rich corona | Standard hepatic; not for spleen |
| -10 to +5 mV | Spleen | 0.15-0.40 | Reduced ApoE; diversified opsonins | Target for spleen |
| -30 to -10 mV | Spleen and liver | 0.10-0.30 | Phosphatidylserine ligands; IgM | Balance transit vs. uptake |
The PEG coating on LNPs serves as both a steric barrier against nonspecific protein adsorption and a determinant of particle residence time in circulation. For spleen targeting, PEGylation parameters must be tuned differently than for hepatic delivery: the goal is not maximal circulation time but sufficient shielding to avoid immediate hepatic capture while permitting splenic recognition. Short-chain PEG-lipids with C14 anchors (DMG-PEG) produce LNPs that are predominantly hepatic, as rapid PEG desorption exposes the underlying lipid membrane for ApoE binding before particles reach the spleen. Long-chain PEG-lipids with C18 or C24 anchors (DSG-PEG) provide more durable shielding, allowing a larger fraction of the injected dose to reach and accumulate in the spleen. Pegylated lipid nanoparticles formulated with C18-PEG at 1.5-2.5 mol% have demonstrated spleen-to-liver expression ratios 3- to 5-fold higher than equivalent C14-PEG formulations. PEG shedding kinetics matched to splenic transit time (4-12 h) maximize functional delivery. LNP PEG-lipid optimization systematically identifies the anchor length, molar density, and shedding profile for each formulation.
Table.4 PEG-Lipid Parameters and Spleen Tropism.
| Parameter | Liver-Favoring | Spleen-Favoring | Mechanistic Basis | Window for Spleen |
| Anchor | C14 (rapid desorption) | C18/C24 (durable) | Longer anchors delay ApoE adsorption | C18 IV; C14 local routes |
| Molar Density | <1.0 or >3.0 mol% | 1.5-2.5 mol% | Balance shielding vs. uptake | 1.5-2.5 mol% |
| Shedding t1/2 | <2 h or >24 h | 4-12 h | Coincides with splenic PK | 4-12 h IV |
The ionizable lipid's apparent pKa determines the cell types in which functional payload delivery occurs. Ionizable lipids with pKa 6.2-6.5 are optimized for hepatocyte delivery; shifting pKa outside this range (below 6.0 or above 6.8) reduces hepatic expression and can redirect functional delivery toward splenic immune cells. LNP ionizable lipid optimization is a practical approach for identifying spleen-favoring lipids. The helper phospholipid also influences organ tropism: replacing DSPC with DOPE promotes the hexagonal phase transition required for endosomal membrane fusion, enhancing payload release in phagocytic immune cells. LNP helper lipid optimization and LNP cholesterol optimization are integral to a comprehensive spleen-targeting strategy.
Table.5 Ionizable and Helper Lipid Parameters for Spleen-Tropic LNPs.
| Lipid Parameter | Conventional / Hepatic Setting | Spleen-Targeted Setting | Effect on Splenic Delivery |
| Ionizable lipid pKa | 6.2-6.5 (tuned for hepatocyte endosomal maturation) | Below 6.0 or above 6.8 (outside hepatic window) | Reduces hepatocyte expression; redirects functional payload delivery toward splenic immune cells |
| Helper phospholipid | DSPC (lamellar, high stability) | DOPE (fusogenic, hexagonal-phase favoring) | Promotes endosomal membrane fusion; improves payload release in phagocytic splenic macrophages and DCs |
| Cholesterol molar ratio | ~38.5 mol% (standard serum stability) | 20-30 mol% (increased membrane fluidity) | Enhances membrane fluidity; may improve splenic filtration efficiency at the cost of reduced storage stability |
BOC Sciences can screen particle size, surface charge, ionizable lipids, helper lipids, and PEG architecture to identify a formulation that promotes spleen-selective delivery while reducing liver-dominant distribution.
While passive targeting redirects LNPs to the spleen at the organ level, active targeting strategies provide an additional layer of precision by directing particles toward specific splenic immune cell populations. This is particularly important when the therapeutic goal requires engagement of a defined cell subset. Active targeting ligands are displayed on the LNP surface, typically via PEG-lipid tethers, and engage cognate receptors differentially expressed on target immune cells. The following sections organize active targeting by target cell type.
Splenic DCs — particularly the cross-presenting CD8+ subset — are the primary orchestrators of T cell priming and the most valuable targets for cancer vaccine and tolerogenic applications. Antibody-conjugated lipid nanoparticles directed against CD11c deliver LNPs specifically to splenic DCs, while anti-CD205 (DEC-205) targets the endocytic receptor used for efficient antigen presentation. Mannose and fucose conjugates engage C-type lectin receptors (CD206, DC-SIGN) abundantly expressed on DCs. The key challenge is avoiding the endosomal trap: CLR-mediated uptake efficiently delivers LNPs into endolysosomes, but functional payload activity requires escape — making LNP endosomal escape evaluation an essential companion assay. Mannose-conjugated lipid nanoparticles increase splenic DC uptake 3- to 8-fold relative to unmodified LNPs. From a targeting-strategy perspective, DC-directed delivery is the preferred route when the objective is antigen-specific T cell (cellular) immunity — for example, cancer neoantigen vaccines or antiviral T cell responses — because DCs are the only splenic APCs that efficiently cross-present antigen to naive CD8+ T cells, seeding the effector and memory T cell pools needed for tumor control or pathogen clearance.
Red pulp and marginal zone macrophages are the first splenic cells to encounter blood-borne LNPs and are central to both innate immune activation and tolerogenic signaling. Anti-CD169 (SIGLEC-1) antibodies target marginal zone metallophilic macrophages — a strategically positioned population at the blood-white pulp interface that efficiently transfers antigen to neighboring B cells. Scavenger receptor ligands (MARCO, SIGN-R1) engage marginal zone macrophages via their natural clearance function. For siRNA delivery to macrophages, the dominant challenge is endolysosomal degradation; fusogenic helper lipids and endosomolytic peptides are required to achieve meaningful gene silencing. Erythrocyte membrane coating represents a biomimetic macrophage-directed approach, exploiting the spleen's natural role in senescent red cell clearance to achieve 3- to 5-fold splenic accumulation. The decision to target macrophages is driven by goals of rapid innate immune activation or antigen-specific tolerance: as the first splenic cells to capture blood-borne LNPs, marginal zone macrophages can present self-antigen under tolerogenic signals to expand regulatory T cells, a mechanism of particular interest for autoimmune tolerance approaches.
B cell follicles and marginal zone B cells are responsible for rapid, high-titer antibody responses — the goal of prophylactic and therapeutic vaccines. Anti-CD19 and anti-CD20 conjugates direct LNPs to B cell follicles, where antigen payloads drive germinal center formation and affinity maturation. Anti-CD21 (CR2) antibodies engage the complement receptor that bridges innate and adaptive humoral immunity. Aptamer-conjugated lipid nanoparticles offer a chemically defined alternative to antibodies for B cell targeting, with site-specific conjugation and reduced immunogenicity. Marginal zone B cell engagement via anti-IgM or glycoprotein ligands produces accelerated IgM responses valuable for pandemic preparedness applications. B cell-directed targeting is selected when the therapeutic aim is fast, high-titer antibody (humoral) immunity: marginal zone B cells differentiate into antibody-secreting plasma cells within 24-48 h of antigen encounter, so this route is preferred for prophylactic and therapeutic vaccines where rapid seroconversion is decisive.
Although T cells lack the phagocytic capacity of macrophages and DCs, direct LNP engagement of splenic T cells — particularly within the PALS — is valuable for tolerogenic approaches and Treg expansion. CCL21-derived peptides direct LNPs toward CCR7-expressing T cells that home to T cell zones. CD4 and CD8 aptamers enable T cell subset-specific delivery for tolerance induction or effector programming. Bispecific antibody-targeted LNPs that simultaneously engage a DC marker (CD40) and a T cell marker (CD3) promote immunological synapse formation, physically bringing antigen-bearing APCs and responding T cells into proximity within the splenic white pulp. Peptide-functionalized lipid nanoparticles provide a scalable, chemically defined platform for T cell-directed strategies. Direct T cell targeting is chosen to expand regulatory T cells for tolerance or to engage effector T cells already resident in the PALS; bispecific DC-T bridging is especially useful where localized immune synapse formation is desired, as in combined anti-tumor immunotherapy and tolerance-focused regimens.
Table.6 Splenic Immune Cells and Their Matching LNP Ligands.
| Splenic Immune Cell | Cell-Surface Receptor | LNP Ligand Options |
| Dendritic Cell (DC) | CD11c, CD205 (DEC-205), CD206 (mannose receptor), DC-SIGN (CD209) | Anti-CD11c / anti-CD205 antibody, mannose or mannan, fucose |
| Macrophage (red pulp & marginal zone) | CD169 (SIGLEC-1), MARCO, SIGN-R1, scavenger receptors | Anti-CD169 antibody, erythrocyte membrane coating (CD47), scavenger ligands |
| B Cell (follicle & marginal zone) | CD19, CD20, CD21 (CR2), B cell receptor (IgM) | Anti-CD19 / anti-CD20 antibody, anti-CD21 aptamer, anti-IgM |
| T Cell (PALS) | CCR7 (CCL21 receptor), CD4, CD8 | CCL21-derived peptide, CD4 / CD8 aptamer, bispecific antibody (anti-CD3) |
BOC Sciences supports ligand selection, surface conjugation, spacer and ligand-density optimization, and cell-specific delivery evaluation for splenic dendritic cells, macrophages, B cells, and T cells.
Different therapeutic cargoes behave very differently once they reach the spleen, so the way you build the LNP has to change with the payload. The table below summarizes, for each major payload class, the main delivery hurdle and the concrete formulation steps that steer that payload into splenic tissue and the right immune cells.
Messenger RNA is fragile: extracellular RNases begin degrading it the moment it leaves the formulation, and even after a cell internalizes the LNP, much of the mRNA is destroyed in endosomes before it can be translated. To make mRNA work in the spleen, you first build a passive spleen-tropic LNP in the 40–80 nm range with a near-neutral surface charge and trimmed PEG density so the particle filters into the spleen instead of being trapped in the liver. You then add a mannose or anti-CD11c ligand so dendritic cells in the marginal zone and white pulp preferentially take it up, turning those cells into local factories that present antigen and prime T-cell immunity. For tailored constructs, see lipid nanoparticles for mRNA delivery.
Self-amplifying RNA and circular RNA are larger and more structured than standard mRNA, so they need higher encapsulation efficiency and a lipid mix that stays stable long enough for durable expression. Here the priority is the passive route: a spleen-tropic LNP with a slightly higher N/P ratio and a more fusogenic helper lipid lets the big cargo enter splenic cells efficiently. Because these constructs express for a long time once inside, active ligands are often unnecessary — getting the particle into the spleen is enough to sustain a prolonged immune signal. Related options are described under lipid nanoparticles for saRNA delivery.
Short oligonucleotides such as siRNA and ASO are quickly trapped and degraded in the endolysosomal pathway, so the bottleneck is escape rather than entry. You build a passive spleen-tropic LNP and incorporate DOPE or an endosomolytic additive to break the endosome, then apply an anti-CD169 ligand or an erythrocyte-mimetic coating that directs the particle specifically to splenic macrophages, the cell type most relevant for innate immune modulation and tolerogenic programs. Background on the platform is available at lipid nanoparticles for siRNA delivery.
Proteins and peptides lose their folded, active shape if you force them into a lipid core, so the challenge is preserving structure while still reaching splenic cells. Remote loading keeps the cargo in its native conformation, and you then pair the passive spleen-tropic LNP with anti-CD19 or anti-CD20 ligands that home to B cells in the white pulp — useful when the goal is to drive antibody responses or tolerize B-cell compartments. See protein encapsulation in LNPs and peptide encapsulation in LNPs for the underlying methods.
Delivering CRISPR ribonucleoprotein means getting a large Cas protein–guide complex into the cytoplasm and then into the nucleus, a two-step journey that ordinary LNPs handle poorly. You select an ionizable lipid with strong endosomal escape and append a subset-specific active ligand so the RNP is deposited directly into the target splenic cell population — whether dendritic cells, B cells, or macrophages — rather than relying on passive distribution alone. Platform details are at lipid nanoparticles for CRISPR RNP delivery.
Combining an antigen with an adjuvant, or two nucleic acids, only helps if both arrive in the same cell at the same time. You co-encapsulate both payloads in a single passive spleen-tropic LNP so they share one fate, then attach a dendritic-cell ligand so the combined cargo reaches antigen-presenting cells together — this spatiotemporal coordination is what turns co-delivery from a formulation trick into an immune outcome. Explore the approach via lipid nanoparticles for co-delivery.
Table.7 Spleen-Targeted Delivery Strategies Organized by Payload Type.
| Payload | Key Delivery Challenge | How to Achieve Spleen-Targeted Delivery |
| mRNA | RNase degradation and poor endosomal escape limit the functional dose reaching splenic cells. | Build a passive spleen-tropic LNP (40–80 nm, near-neutral zeta, reduced PEG density) so the particle filters into the spleen, then add mannose or anti-CD11c ligand to drive uptake by marginal-zone and white-pulp dendritic cells. |
| saRNA / circRNA | Large, structured cargo needs high encapsulation and durable expression. | Use a spleen-tropic passive LNP with a higher N/P ratio and a more fusogenic helper lipid to favor splenic filtration and cell entry; long expression makes active ligands optional. |
| siRNA / ASO | Endolysosomal trapping destroys the oligonucleotide before it acts. | Pair a passive spleen-tropic LNP with DOPE or endosomolytic additives for escape, and apply an anti-CD169 ligand or erythrocyte-mimetic coating to route cargo into splenic macrophages. |
| Protein / Peptide | Folding and activity are lost during forced encapsulation. | Use remote loading to preserve conformation, then steer the passive LNP with anti-CD19/CD20 ligands toward splenic B cells in the white pulp. |
| CRISPR RNP | The Cas complex must reach the cytoplasm and then the nucleus. | Select an ionizable lipid with strong endosomal escape and append a subset-specific active ligand to deposit the RNP directly into the target splenic cell population. |
| Co-Delivery | Two payloads must reach the same cell with matched timing. | Co-encapsulate both agents in one passive spleen-tropic LNP and attach a dendritic-cell ligand so agonist and antigen arrive at antigen-presenting cells together. |
Based on your payload properties, target splenic cells, administration route, and immune-modulation objective, BOC Sciences designs and produces customized spleen-targeted LNPs with appropriate encapsulation, formulation, and surface-engineering strategies.
Problem: Despite spleen-targeting design, the liver remains dominant (splenic signal<5% of total biodistribution) — the most common obstacle.
Causes: (a) PEG-lipid anchor too short (C14) desorbs before splenic arrival; (b) insufficient anionic helper lipid content to shift the protein corona; (c) ionizable lipid pKa in hepatic-favoring 6.2-6.5 window; (d) particle size >100 nm favoring Kupffer clearance.
Solutions: Replace C14 with C18 DSG-PEG at 1.5-2.5 mol%; titrate anionic helper lipid content across a formulation-specific range; screen pKa-outside-range lipids via LNP ionizable lipid optimization; reduce diameter to 40-60 nm. Nanoparticle in vivo imaging services provide quantitative organ biodistribution for iterative optimization.
Problem: Robust splenic accumulation confirmed, but functional activity (luciferase, silencing, presentation) negligible — the "uptake-expression gap," common in phagocytic cells.
Causes: Endolysosomal trapping; insufficient ionizable lipid fusogenicity; helper lipid favoring lamellar (not hexagonal) phase; PEG densities blocking membrane fusion.
Solutions: Replace DSPC with DOPE; increase ionizable lipid to 50-60 mol%; incorporate pH-responsive peptides at 0.5-2 mol%. Use LNP endosomal escape evaluation and nanoparticle intracellular localization detection to distinguish uptake from productive delivery.
Problem: Anionic helper lipids or ligand conjugates show colloidal instability, cross-species corona variability, or lost selectivity upon scale-up (0.5 mL → 200 mL).
Causes: Reduced electrostatic repulsion from anionic lipids; ligand desorption; mouse vs. human plasma corona differences; altered microfluidic mixing at scale.
Solutions: Screen cryoprotectants via LNP excipient screening services; characterize corona in mouse and human plasma; implement LNP process scale-up services with DoE; apply LNP critical quality attributes and QC testing at each scale gate.
BOC Sciences provides systematic troubleshooting — from biodistribution analysis and endosomal escape assessment to scale-up process optimization — to resolve spleen delivery bottlenecks.
The spleen is one of the few organs where naive T cells and antigen-presenting dendritic cells are concentrated in the same anatomical compartment — the white pulp. This proximity is the mechanistic foundation for cancer immunotherapy delivered to the spleen. When a spleen-targeted LNP carrying tumor neoantigen mRNA reaches splenic dendritic cells, those DCs translate the mRNA and immediately present the resulting peptide on MHC class I and class II molecules. Because the primed T cells are already inside the white pulp, immune synapse formation happens on the spot without the migration delay inherent to lymph-node-based approaches. The result is a coordinated priming event that produces both effector CD8+ T cells capable of peripheral tumor infiltration and a durable memory pool for long-term surveillance. This inherent architectural advantage — concentrated APC-T cell contact within a single compartment — makes the spleen a uniquely efficient priming site for anti-tumor cellular immunity.
Most mRNA vaccines are injected intramuscularly, which means the antigen is expressed mainly in myocytes and picked up by local draining lymph nodes. The spleen receives very little of that dose. Yet the spleen is where the body's largest reservoir of B cells resides, including marginal zone B cells that are pre-positioned to respond to blood-borne antigens within hours. A spleen-targeted LNP formulation changes the delivery equation: instead of relying on antigen to trickle into the spleen secondhand, it deposits the mRNA directly into splenic tissue where B cell follicles and follicular dendritic cells can engage it immediately. Marginal zone B cells differentiate into IgM- and IgG-secreting plasma cells within 24-48 hours of antigen encounter, giving spleen-targeted vaccines an inherent speed advantage. At the same time, the germinal center reaction inside the white pulp drives affinity maturation, producing high-quality antibodies that last. Lipid nanoparticle for vaccine platforms that achieve splenic delivery therefore address two practical goals at once: faster antibody onset for scenarios where time matters, and durable humoral protection that may reduce the number of booster doses needed.
Autoimmune disease results from a breakdown in self-tolerance, and the standard answer — broad immunosuppression — controls symptoms without fixing the underlying recognition error. The spleen provides a more targeted option because it already runs a built-in tolerogenic filter: splenic dendritic cells routinely present self-antigens to T cells without co-stimulatory signals, naturally inducing anergy, deletion, or regulatory T cell conversion. A spleen-targeted LNP carrying the disease-relevant self-antigen delivers that antigen directly into this quiet, non-inflammatory presentation pathway. The spleen's high blood flow and dense APC network ensure broad antigen exposure, and co-delivery of a tolerogenic signal can reinforce the regulatory instruction. The outcome is antigen-specific tolerance — the immune system learns to ignore the problem-causing antigen while keeping the rest of its defenses intact, addressing the root cause rather than just the downstream inflammation.
BOC Sciences provides integrated support — from spleen-tropic LNP formulation design through in vivo biodistribution and immune response evaluation — to advance your spleen-targeted LNP program.
BOC Sciences provides comprehensive spleen-targeted LNP development services spanning the entire workflow. Our approach begins with target definition — identifying splenic cell population(s), payload class, and immunological outcome — and proceeds through formulation library construction, physicochemical characterization, and biological screening. LNP ionizable lipid optimization evaluates 50-200+ candidates; LNP lipid ratio optimization varies composition to maximize splenic delivery. Lipid nanoparticle formulation is supported by nanoparticle analysis and characterization — DLS, zeta potential, cryo-EM, encapsulation efficiency, stability — at every stage.
For cell-type-specific delivery, BOC Sciences offers a full suite of conjugation services: mannose-conjugated, antibody-conjugated, peptide-functionalized, and aptamer-conjugated lipid nanoparticles, each with defined QC endpoints. Nanoparticle functionalization services encompass ligand density quantification and receptor binding validation. Nanoparticle cellular uptake testing provides quantitative dose-response in primary splenocytes; nanoparticle intracellular localization detection distinguishes surface-bound, endosomal, and cytosolic populations.
Nanoparticle cellular and in vivo evaluation integrates organ-level biodistribution with splenocyte subpopulation flow cytometry to confirm engineered LNPs reach and transfect intended targets. Nanoparticle in vivo imaging services provide IVIS quantification; functional payload assays confirm biological activity. For programs advancing to larger scale, LNP process scale-up services transfer microfluidic parameters with QC consistency. The final deliverable is a lead candidate with defined specifications, validated spleen-tropic biodistribution, confirmed cell engagement, and demonstrated functional activity.
Table.8 BOC Sciences Spleen-Targeted LNP Service Offerings.
| Service | Scope | Deliverables | Inquiry |
| Spleen-Targeted LNP Development | Targeting strategy, lipid screening, optimization | Lead formulations; size/PDI/zeta/EE%; spleen/liver ratio report | Inquiry |
| Ionizable Lipid Optimization for Spleen Tropism | 50-200+ lipid library; pKa; structure-tropism analysis | Ranked candidates; recommended lead lipid | Inquiry |
| Lipid Nanoparticle Functionalization Services | Mannose/antibody/peptide/aptamer; density; binding validation | Conjugated LNPs; cell-type-specific uptake data | Inquiry |
| Lipid Nanoparticle In Vivo Imaging Services | IVIS; organ biodistribution; splenocyte flow; functional assay | PK-PD correlation; immunogenicity report | Inquiry |
| LNP Scale-Up and Process Development | Microfluidic transfer; DoE; batch consistency | Scalable process; development batches with QC | Inquiry |
Spleen-targeted LNP delivery has emerged as a transformative strategy for immune modulation, redirecting nucleic acid and protein payloads from the default hepatic clearance pathway toward the body's largest and most immunologically strategic secondary lymphoid organ. The design principles span passive approaches — particle size 40-80 nm, near-neutral zeta potential (-10 to +5 mV), long-chain PEGylation (C18, 1.5-2.5 mol%), ionizable lipids with pKa outside the hepatic-favoring window — to active targeting engaging specific splenic immune cell populations via mannose, antibody, peptide, aptamer, and biomimetic ligands organized by DC, macrophage, B cell, and T cell directionality. For research teams navigating spleen-selective LNP development, BOC Sciences offers integrated support from targeting strategy design through formulation optimization, ligand conjugation, characterization, and in vivo evaluation, translating spleen-targeting concepts into functionally validated candidates.
References
